Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
283.61
+10.70 (3.92%)
Jan 29, 2026, 9:41 AM EST - Market open
Krystal Biotech Revenue
Krystal Biotech had revenue of $97.80M in the quarter ending September 30, 2025, with 16.65% growth. This brings the company's revenue in the last twelve months to $373.16M, up 54.51% year-over-year. In the year 2024, Krystal Biotech had annual revenue of $290.52M with 473.02% growth.
Revenue (ttm)
$373.16M
Revenue Growth
+54.51%
P/S Ratio
21.11
Revenue / Employee
$1,356,960
Employees
275
Market Cap
8.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.52M | 239.82M | 473.02% |
| Dec 31, 2023 | 50.70M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.16B |
| Halozyme Therapeutics | 1.24B |
| Arrowhead Pharmaceuticals | 829.45M |
| Caris Life Sciences | 649.06M |
| Axsome Therapeutics | 561.26M |
| Rhythm Pharmaceuticals | 174.33M |
| Cytokinetics | 87.21M |
| Praxis Precision Medicines | 7.46M |
KRYS News
- 13 days ago - Krystal Biotech: Beyond VYJUVEK Commercialization - Seeking Alpha
- 13 days ago - These under-the-radar stocks combine fast growth with big upside potential - Market Watch
- 16 days ago - Krystal Biotech, Inc. (KRYS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 17 days ago - Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 20 days ago - Krystal Biotech, Inc. (KRYS) Discusses Positive Interim Results and Next Steps for Cystic Fibrosis Program KB407 Transcript - Seeking Alpha
- 2 months ago - Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 2 months ago - Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth - Seeking Alpha
- 3 months ago - Krystal's Q3: Platform Designation Adds Pipeline Leverage As Vyjuvek Scales (Rating Upgrade) - Seeking Alpha